Alternate Name(s):
Dalacin C
Classification:
Antibiotic
Original Date:
March 1992
Revised Date:
April 2017
Indications:
- Treatment of infections due to anaerobic bacteria and some Staphylococci
Administration:
- IV intermittent infusion: over 15 - 30 minutes
Dosage:
< 1.2 kg:
- 0 - 4 weeks: 10 mg/kg/day divided Q12H
1.2 - 2 kg:
- 0 - 7 days: 10 mg/kg/day divided Q12H
- > 7 days: 15 mg/kg/day divided Q8H
> 2 kg :
- 0 - 7 days: 15 mg/kg/day divided Q8H
- > 7 days: 20 mg/kg/day divided Q6H
- Reduce dosage in patients with severe renal or hepatic impairment. Refer to available references or clinical pharmacist for dosage adjustment
Side Effects:
- GI: pseudomembranous colitis (due to Clostridium difficile overgrowth)-characterized by bloody diarrhea, abdominal pain- treat with metronidazole or oral vancomycin
Parameters to Monitor:
- Observe for changes in bowel frequency and stools, abdominal tenderness
Reconstitution and Stability:
CHEO:
- Clindamycin 150 mg/mL
- Take 2 mL (300 mg) and add to 23 mL D5W or 0.9%NaCl
- Final concentration: 12 mg/mL
TOH:
- Clindamycin 150 mg/mL
- Take 1 mL (150 mg) and add to 24 mL D5W
- Final concentration: 6 mg/mL
Compatibility:
- Solutions Compatible: D5W, D10W, 0.9% NaCl, dextrose-saline combinations
- Y-site Compatible: acyclovir, gentamicin, heparin, hydromorphone, midazolam, milrinone, morphine, TPN
Incompatible: azithromycin, caspofungin, fluconazole, pantoprazole
References:
-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc.; 2015.
-American Society on Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition. Bethesda: American Society of Health-System Pharmacists; 2017